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Abstract Tamoxifen and aromatase inhibitors are associ-
ated with side effects which can significantly impact quality of
life (QoL). We assessed QoL in the Tamoxifen Exemestane
Adjuvant Multinational (TEAM) Trial and compared these
data with reported adverse events in the main database. 2,754
Dutch postmenopausal early breast cancer patients were ran-
domized between 5 years of exemestane, or tamoxifen
(2.5–3 years) followed by exemestane (2.5–2 years). 742
patients were invited to participate in the QoL side study and
complete questionnaires at 1 (T1) and 2 (T2) years after start of
endocrine treatment. Questionnaires comprised the EORTC
QLQ-C30 and BR23 questionnaires, supplemented with
FACT-ES questions. 543 patients completed questionnaires at
T1 and 454 patients (84 %) at T2. Overall QoL and most
functioning scales improved over time. The only clinically
relevant and statistically significant difference between treat-
ment types concerned insomnia; exemestane-treated patients
reported more insomnia than tamoxifen-treated patients. Dis-
crepancy was observed between QoL issue scores reported by
the patients and adverse events reported by physicians. Certain
QoL issues are treatment- and/or time-specific and deserve
attention by health care providers. There is a need for careful
inquiry into QoL issues by those prescribing endocrine treat-
ment to optimize QoL and treatment adherence.
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Background
The majority of breast cancer patients are diagnosed at
postmenopausal age and most have hormone receptor-
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positive tumors. Over time, adjuvant endocrine therapy has
increasingly been used to reduce disease recurrence and
improve survival [1]. Presently, optimal endocrine therapy
consists of at least 5 years of treatment including an aro-
matase inhibitor (AI), either given upfront or as part of a
sequential treatment regimen following tamoxifen [2].
Both regimens are appropriate treatment options for post-
menopausal hormone receptor-positive breast cancer
patients [2, 3]. However, many patients on endocrine
therapy are confronted with adverse effects, which may
negatively impact QoL, treatment compliance, and may
then lead to a reduced survival [4, 5]. The impact of long-
term endocrine treatment on quality of life (QoL) in post-
menopausal breast cancer patients may therefore be an
important issue of deliberation regarding the choice for a
specific adjuvant treatment strategy.
Both tamoxifen, a selective estrogen receptor modulator,
and AIs, which potently inhibit the aromatase enzyme
(involved in the conversion of androgens to estrogen), are
associated with a variety of adverse effects. Tamoxifen is
associated with thromboembolic complications and endo-
metrial cancer while AIs show fewer life-threatening side
effects but more readily give rise to sometimes invalidating
symptoms such as hot flashes, arthralgias, vaginal dryness,
and osteoporosis [6, 7]. Variations in the types and sever-
ities of adverse effects associated with the use of either
tamoxifen or an AI may result in differences in the domains
of QoL affected in patients using either endocrine
treatment.
So far, several trials have investigated QoL in patients
using adjuvant endocrine therapy, but only four have
compared QoL in patients treated with tamoxifen versus
an AI [8–12]. It is difficult to compare these studies due to
variations in trial design, starting time of the AI, and type
of AI used. To the best of our knowledge, the ATAC QoL
study is the only large trial that compared QoL from the
start of endocrine therapy in patients treated with tamox-
ifen versus an AI upfront [9]. In the Tamoxifen Exemes-
tane Adjuvant Multinational (TEAM) trial (Netherlands
Trial Register NTR267), postmenopausal, hormone
receptor-positive early breast cancer patients were ran-
domized to either 5 years of exemestane upfront or
2.5–3 years tamoxifen followed by 2–2.5 years of exe-
mestane [2]. There was a major participation in the TEAM
study from the different hospitals throughout the Nether-
lands, therefore, this study provided a good opportunity
for studying the effects of exemestane and tamoxifen on
QoL in a homogeneous cohort of Dutch breast cancer
patients. Moreover, we were able to relate relevant QoL
issues reported by patients in this side study to the adverse
events involved with these issues reported by the same




The study design and patient eligibility criteria for the
TEAM trial have been described previously [2]. In the
Netherlands, the study was initiated in 76 hospitals and
details also have been described previously [13]. The
TEAM QoL side study was an open multicenter study in
which 45 Dutch TEAM centers participated. The side study
protocol was approved separately by central and local
ethics authorities before the enrollment of patients.
Patients and data collection
Patients who were randomized between January 2nd, 2003
and December 29th, 2004 and were event-free were invited
to participate in the TEAM QoL side study. Patients
received a letter together with the first QoL questionnaire at
1 year after treatment randomization (further referred to as
time point 1; T1). Participating patients who returned the
first questionnaire and were disease-free 2 years after
randomization received the second questionnaire 1 year
after T1 (further referred to as time point 2; T2). Patients
included in the sequential arm received the second ques-
tionnaire before the switch from tamoxifen to exemestane.
No questionnaire was sent at baseline (time of diagnosis
and treatment) as the results regarding QoL may potentially
be biased, due to the recent knowledge of breast cancer
diagnosis and impending treatment, which is known to
have a negative impact on QoL. Furthermore, treatment
was allocated by randomization, hence there is essentially
no indication for baseline imbalance in QoL data between
both treatment arms [14]. Patient, tumor, treatment, and
survival data were collected through the main TEAM Da-
tacenter in Leiden, the Netherlands. In the main trial,
patients were seen every 3 months in the first year, twice
yearly in the second year and at least yearly thereafter. In
the main trial, data on adverse events experienced by
patients were recorded during follow-up visits by local
investigators and centrally collected at the main datacenter.
For the QoL participants, we selected adverse events
reported within the first 2 years that were associated with
the relevant QoL issues observed from the central database.
Questionnaires
Data on QoL were obtained using the European Organization
for Research and Treatment of Cancer Quality of Life Ques-
tionnaire Version 3.0 (EORTC QLQ-C30) and the EORTC
Breast Cancer Module questionnaire (QLQ-BR23), both
translated into Dutch and previously validated [15, 16]. Both
questionnaires were used after authorization by the EORTC
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Quality of Life Study Group. The EORTC QLQ-C30 is
composed of five functioning scales (physical functioning,
role functioning, cognitive functioning, emotional function-
ing, and social functioning), a global health status/QoL scale,
three symptom scales (fatigue, pain, nausea/vomiting), and six
single items (dyspnea, appetite loss, sleep disturbance, con-
stipation, diarrhea, and financial impact). The EORTC QLQ-
BR23 is a validated tool designed for breast cancer patients
with varying disease stages and treatment modalities and
consists of 23 items that assess disease symptoms, side effects,
body image, sexual functioning, future perspectives, therapy
side effects, breast and arm symptoms, and hair loss. Items that
specifically assess side effects of chemotherapy were not
applicable for the current study. In addition, the Functional
Assessment of Cancer Therapy-Endocrine Subscale (FACT-
ES) questionnaire was designed and validated to measure QoL
in breast cancer patients treated with endocrine therapies [17].
Of the 18 items, 13 were included in our questionnaire (as
other items were already included through the EORTC QLQ-
C30 or BR23 questionnaires), resulting in three endocrine
symptom scales (menopausal complaints, weight complaints,
and vaginal complaints).
Based on standard EORTC scoring procedures, all scales
were linearly converted to a 0-to-100 scale. Missing data
were treated according to published recommendations [18].
For scales evaluating global health and functioning, higher
scores represent higher levels of functioning and health
status. For the evaluation of symptoms, higher scores cor-
respond to more problems and higher levels of complaints.
Relevant patient-reported outcomes
Regarding QoL, the following items were investigated: (1)
the difference between the QoL scores for patients using
tamoxifen versus exemestane, (2) the difference between
the two time points (T1 and T2), and (3) the interaction
between treatment arm and time. A difference in score of at
least eight points between groups was considered clinically
relevant, and has been demonstrated to be a reasonable cut-
off for clinical significance for a range of QoL endpoints
[19]. Prior surgery was taken into account for analyses of
body image, sexual functioning, and sexual enjoyment.
To study the association between the relevant QoL
issues as reported by the patients and the related adverse
events recorded for these patients by their treating physi-
cians in the main database, patients whose questionnaire
item scores were worse than the mean EORTC QLQ-C30
and BR23 reference scores were considered for comparison
[20].
Statistical analysis
All data were analyzed using the statistical package SPSS
for Windows 17.0 (SPSS Inc, Chicago, IL, USA).
Descriptive data are given as mean (SD) or median (range).
The t test was used to compare frequencies between groups.
Linear mixed models were used to assess changes over time
for overall QoL and for separate components of QoL.
Results
Demographics
A total of 742 Dutch patients were invited to participate in
the QoL side study (Fig. 1). Five-hundred-forty-three
patients (73 %) completed the first questionnaire, of which
454 (84 %) also completed the second questionnaire.
Dutch subset TEAM 
N = 2754 
Assigned to tamoxifen 
N = 1379 
Assigned to exemestane 
N = 1375 
Invited to QoL side study 
N = 373 
Invited to QoL side study 
N = 369 
Completed 1st questionnaire 
N = 270 
Completed 1st questionnaire 
N = 273 
Completed 2nd questionnaire 
N = 227 
Completed 2nd questionnaire 
N = 227 
Fig. 1 Patient selection
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Baseline characteristics of the responding patients and the
total group of Dutch TEAM patients are shown in Table 1.
The distribution of clinicopathological and treatment
characteristics of patients participating in the QoL side
study was similar to that of the entire cohort of Dutch
TEAM trial patients, except for the distribution of age,
hormone receptor status, and prior chemotherapy (yes/no).
Of the patients participating in the TEAM QoL side study,
most were older than 60 years, had node-positive disease,
and underwent a sentinel lymph node procedure followed
by an axillary lymph node dissection. Almost 50 % of the
tumors were smaller than 20 mm and approximately half of
the patients were treated by mastectomy.
QoL: tamoxifen versus exemestane
The results regarding QoL-items are shown in Table 2. In
general, the scores for the various issues did not differ sig-
nificantly between patients using tamoxifen versus exemes-
tane. Patients allocated to tamoxifen showed superior scores
for emotional functioning and sexual functioning (p = 0.048
and p = 0.024 respectively) than exemestane users. Treat-
ment with exemestane did not show superior results compared
to tamoxifen for any of the functioning scales. Regarding
individual symptoms, patients who received tamoxifen had
fewer complaints of fatigue, dyspnea, insomnia, and arm
symptoms than patients receiving exemestane. For ‘‘fatigue,’’
the results were unrelated to the administration of chemo-
therapy (data not shown). Only for insomnia, the differences
between the two treatment types were clinically significant
(more than eight points difference between tamoxifen and
exemestane), observed at both time points (Fig. 2). The
endocrine symptom scales that were assessed using the
FACT-ES included menopausal, weight, and vaginal com-
plaints. These scores did not differ between treatment arms.
The global health status scale represents an overall
summary measurement of QoL. With respect to either
treatment group, there was no difference in global health
status/overall QoL (Table 2). Interestingly, the reported
overall QoL was higher than the reference value of the
EORTC QLQ-C30 ([75 vs. 62 points).
QoL: changes over time
Changes in QoL items were assessed over the 1-year period
between T2 and T1 for the total group of patients, as there
were no relevant differences between the two treatment
types. We found that over time, most functioning scales
improved, except for physical functioning, sexual func-
tioning, and sexual enjoyment (p \ 0.01). Of note, fewer
patients completed the questions concerning sexual func-
tioning and enjoyment compared to the other items (data not
shown). Over time, there was also no change in global
health status; neither improvement nor deterioration. Con-
cerning the individual symptom scales, a significant
improvement was found for the following items: fatigue,
nausea and vomiting, appetite, breast symptoms, and side
effects of systemic therapy. Again, these results for fatigue
were unrelated to the administration of chemotherapy (data
not shown). A clinically significant difference over time
was only established for breast symptoms.
QoL: interaction between treatment arm and time
Irrespective of treatment, most assessed items improved
from T1 to T2. Only for the functioning scale ‘‘Future
perspective’’ did an interaction exist between treatment and
time: patients using exemestane improved more compared
to patients using tamoxifen.
QoL compared to relevant adverse events issues
reported in the TEAM trial
The QoL side study scores for sexual functioning and for
sexual enjoyment were below the mean EORTC QLQ-C30
reference score for 58 % of patients and 72 % of patients,
respectively, at T1; and values were similar at T2 [20]. In
contrast, adverse events related to sexual functioning and/
or sexual enjoyment from the central database, including
genital or vaginal discharge, decreased/loss of libido,
vaginal dryness, and vulvovaginal disorders, were only
documented for 3 % of the QoL participants. Concerning
insomnia, almost 60 % of the QoL patients had a higher
score compared to the mean reference score of the EORTC
at T1 and T2 (indicating more sleeping problems), while in
the central database, insomnia was recorded as adverse
event by only 4 % of the QoL study participants [20].
Lastly, fatigue was reported as adverse event by 12 % of
the QoL participants in the main TEAM database com-
pared to 45 % of QoL study patients having a higher score
than the mean EORTC reference score for fatigue, indi-
cating more complaints, observed at both T1 and T2 [20].
Discussion
The impact of adjuvant endocrine therapy on QoL is an
ongoing discussion in the treatment of breast cancer
patients prescribed long-term endocrine therapy. The cur-
rent standard of practice advocating 5 or more years of
endocrine treatment can therefore be considered cumber-
some in those experiencing severe adverse effects. Both
tamoxifen and AIs have been associated with the devel-
opment of various menopausal symptoms like sleeping
disorders and sexual problems related to the depletion of
circulating estrogens, some of which being severe to the
270 Breast Cancer Res Treat (2012) 134:267–276
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Table 1 Clinicopathological
data of responders and all Dutch
TEAM patients
ALND axillary lymph node
dissection; BCS breast




RT radiotherapy; SLNP sentinel
lymph node procedure;
TEAM NL all patients included
in the Netherlands
Responders TEAM NL p-value
N % N %
Total 543 100 2,753 100
Age
\50–59 200 37 914 33 0.039
60–69 200 37 965 35
C70 143 26 874 32
Body mass index
B25 190 39 919 38 0.589
25–30 188 39 931 38
C30 109 22 601 25
Pathological tumor stage
T1 267 49 1,235 45 0.158
T2 241 45 1,329 48
T3 and T4 32 6 183 7
Pathological nodal stage
pN0 150 29 834 31 0.166
pN1–3 275 53 1,387 52
pN4–9 77 15 327 12
pN C 10 18 3 131 5
Histological grade
Grade I 85 17 420 16 0.896
Grade II 244 48 1,218 47
Grade III 179 35 934 36
Type of tumor
Ductal 404 75 2,047 75 0.891
Lobular 84 16 442 16
Ductal lobular 27 5 129 5
Other 21 4 109 4
Hormone receptor
ER?, PgR? 350 64 1,950 71 0.001
ER?, PgR- 129 24 595 22
ER?, PgRnp 54 10 153 6
ER-, PgR? 10 2 47 2
ER-, PgR- 0 0 6 0
Local therapy
MST, RT- 188 35 1,127 41 0.051
MST, RT? 92 17 401 15
BCS, RT- 7 1 36 1
BCS, RT? 255 47 1,188 43
Treatment axilla
SLNP-, ALND- 0 0 3 0 0.882
SLNP-, ALND? 172 32 885 32
SLNP?, ALND- 127 23 632 23
SLNP?, ALND? 244 45 1,233 45
Chemotherapy
No 348 64 1,941 71 0.002
Yes 195 36 812 30
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point of significantly diminishing QoL. The present
investigation of QoL in patients in the TEAM trial offers
further insight into the impact of either tamoxifen or exe-
mestane on a woman’s QoL during endocrine therapy for
breast cancer.
In the present investigation, a clinically significant dif-
ference was found between the two treatment arms for
insomnia, observed at both time points, indicating more
problems for exemestane users versus those taking
tamoxifen. In general, insomnia is underreported and fre-
quently overlooked in the context of breast cancer treat-
ment. Approximately, half of all breast cancer patients
experience sleeping disorders up to several years post-
diagnosis [21]. The pathophysiological mechanism behind
insomnia in breast cancer patients suggests a relation with
nocturnal hot flashes [22]. Both hot flashes and musculo-
skeletal symptoms have also been associated with the
depletion of circulating estrogens [23]. As exemplified by
Table 2 Overview of the different functioning and symptom scales by time and treatment arm
T1 T2 p-value
Tamoxifen Exemestane Tamoxifen Exemestane Treatment Time Time by treatment
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
EORTC QLQ-C30
Functioning scales
Physical functioning 80 (18) 78 (18) 79 (18) 79 (17) 0.732 0.508 0.132
Role functioning 80 (25) 79 (28) 82 (26) 82 (25) 0.741 0.028 0.826
Cognitive functioning 83 (21) 79 (25) 85 (19) 83 (22) 0.082 0.002 0.179
Emotional functioning 80 (21) 75 (21) 83 (20) 81 (21) 0.048 \0.001 0.273
Social functioning 87 (20) 86 (19) 90 (19) 90 (19) 0.861 0.001 0.397
Global health scale
Global health status 78 (18) 75 (19) 78 (17) 76 (17) 0.074 0.458 0.281
Symptom scales
Fatigue 30 (25) 34 (26) 24 (23) 29 (23) 0.026 \0.001 0.661
Pain 20 (24) 21 (25) 18 (24) 20 (25) 0.216 0.234 0.643
Nausea and vomiting 6 (15) 6 (17) 4 (14) 3 (14) 0.917 0.004 0.395
Symptom single items
Dyspnea 15 (24) 20 (25) 14 (23) 18 (24) 0.032 0.234 0.490
Appetite loss 9 (22) 9 (19) 5 (16) 6 (15) 0.697 0.001 0.511
Insomnia 28 (32) 37 (31) 27 (30) 35 (31) 0.001 0.188 0.869
Constipation 12 (24) 12 (23) 13 (24) 10 (55) 0.319 0.507 0.337
Diarrhea 4 (15) 6 (17) 4 (15) 5 (15) 0.236 0.458 0.823
Financial difficulties 8 (18) 5 (15) 9 (22) 6 (16) 0.076 0.431 0.791
EORTC QLQ-B23
Functioning scales
Body imagea 84 (25) 83 (22) 87 (20) 84 (26) 0.327 0.004 0.294
Sexual functioninga 20 (19) 17 (19) 21 (19) 16 (19) 0.024 0.755 0.208
Sexual enjoymenta 50 (30) 46 (23) 48 (22) 44 (22) 0.172 0.162 0.829
Future perspective 67 (27) 64 (26) 70 (25) 72 (25) 0.710 \0.001 0.028
Symptom scales
Syst therapy side effect 19 (17) 19 (18) 17 (17) 18 (17) 0.964 0.040 0.426
Breast symptoms 22 (19) 19 (19) 16 (19) 14 (19) 0.152 \0.001 0.523
Arm symptomsb 19 (21) 17 (21) 20 (20) 16 (20) 0.027 0.728 0.213
EORTC FACT-ES
Menopausal complaints 26 (21) 26 (21) 24 (20) 26 (20) 0.572 0.093 0.196
Weight complaints 14 (20) 16 (20) 15 (19) 16 (19) 0.186 0.207 0.972
Vaginal complaints 18 (27) 20 (27) 20 (26) 23 (26) 0.337 0.412 0.793
a For this analysis, surgery was a stratification factor: mastectomy versus breast conserving surgery
b For this analysis, surgery was a stratification factor: axillary lymph node dissection (no/yes)
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the MA.17 trial, a significant increase in the incidence of
hot flashes and musculoskeletal symptoms was found in
patients treated with letrozole compared to placebo [11].
Our data regarding more sleeping disorders in exemestane
users suggests that further lowering of postmenopausal
estrogen levels with exemestane may lead to more sleeping
disorders. Unfortunately, this cannot be verified with blood
samples, as these were not collected for our cohort of
TEAM patients.
Patients using exemestane reported less sexual enjoy-
ment and more sexual functioning problems than patients
using tamoxifen. This is similar to the results as found after
1 year of therapy in the US Oncology side study of the
TEAM trial concerning menopausal symptoms [10]. Our
data do show that also after 2–2.5 years of therapy, men-
opausal symptoms persisted over time. In physiological
menopause, the lack of circulating estrogens reduces vag-
inal lubrication, resulting in vaginal dryness and, conse-
quently, dyspareunia [24]. Tamoxifen affects sexual
functioning in terms of decreased libido and the ability to
become aroused and experience orgasm, while AIs cause
vaginal dryness and dyspareunia. Although tamoxifen is
known to have anti-estrogenic properties on breast tissue, it
exerts an estrogen agonist effect on the female genital tract
in postmenopausal women and increases the risk of endo-
metrial cancer [25]. Furthermore, under tamoxifen treat-
ment, the vaginal squamous epithelium is weakly
stimulated and undergoes proliferation and maturation
[26]. It is possible that the abovementioned reasons explain
why sexual functioning may be less affected in tamoxifen-
treated patients than in those treated with exemestane.
Another contributing factor may be that as already said,
exemestane induces further lowering of postmenopausal
estrogens in breast cancer patients. Fewer reports investi-
gated vaginal dryness and dyspareunia in studies with AIs,
but Morales suggest that AIs induce more symptoms of
vaginal atrophy (vaginal dryness and dyspareunia) than
tamoxifen, which parallels our findings that exemestane-
treated patients reported more sexual functioning problems
than tamoxifen-treated patients [27].
Adverse events and reported QoL
Although it is difficult to relate QoL issues as measured
with questionnaires with adverse events as documented by
the physician, we observed striking differences between
these two methods. With respect to specific aspects of QoL
such as sexual functioning, fatigue, and insomnia, signifi-
cantly more patients reported complaints of these items in
the QoL side study than that adverse events related to these
specific complaints were documented in the main TEAM
trial database. This finding reiterates the importance of
thorough investigations on QoL issues and questions the
reliability of the reported adverse events in large multi-
national phase III trials. Ideally, every large clinical trial
assessing efficacy and safety of new oncological treatments
should include a questionnaire-based QoL assessment,
enabling more precise estimation of the associated adverse
events.
Other QoL studies
To date, only a few large randomized trials comparing
adjuvant tamoxifen with an AI have reported on QoL
data (Table 3) [8–12]. Also, it is difficult to compare the
different randomized trials with each other and with our
QoL side study, due to differences in patient populations,
countries of residence, AIs used, timing and of start of
treatment, and the instruments used to assess QoL.
However, regardless of these variations, no large differ-
ences in QoL were seen between tamoxifen and AIs.
The planned nature of the QoL side study using vali-
dated questionnaires as well as the high response rate for
both T1 and T2 questionnaires lends confidence to our
findings. The absence of a baseline measurement may be
considered a shortcoming when assessing changes in QoL
over time; notably, however, baseline measurements of
QoL are likely biased due to recent knowledge of breast
cancer diagnosis in our patient population at the start of
treatment. Due to the randomized nature of this trial, dif-
ferences in baseline QoL with respect to treatment arms are
unlikely [14]. This study is limited by the lack of reporting
consistency of adverse events in the main TEAM trial in
relation to the observed QoL domains affected in patients
in the side study. Concurrently, this may still adequately
reflect variations in reporting by both investigators and
patients alike during clinical visits.
Fig. 2 Insomnia in relation to treatment and time in the TEAM QoL
side study
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Conclusion
Our findings indicate that overall QoL and most function-
ing scales improve with longer therapy duration, both for
patients treated with tamoxifen and exemestane. Never-
theless, certain QoL issues are treatment-specific and
deserve attention by oncology health care providers. Also,
the large number of patients who reported complaints of
sexual functioning, fatigue, and insomnia in the QoL study
was not mirrored by the reported adverse events related to
these complaints in the main TEAM trial database.
Although strictly observational, this large discrepancy
between various QoL issues in the side study and the
related adverse events recorded in the main trial stresses
the need for careful inquiry by those seeing patients
throughout the duration of endocrine treatment to optimize
QoL and ensure adherence to treatment. Further investi-
gation into an optimal reporting approach is warranted.
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